ZIM Laboratories Limited (NSE:ZIMLAB)
68.10
+0.63 (0.93%)
Apr 6, 2026, 3:29 PM IST
ZIM Laboratories Revenue
ZIM Laboratories had revenue of 1.09B INR in the quarter ending December 31, 2025, with 12.80% growth. This brings the company's revenue in the last twelve months to 3.78B, down -2.65% year-over-year. In the fiscal year ending March 31, 2025, ZIM Laboratories had annual revenue of 3.79B with 3.16% growth.
Revenue (ttm)
3.78B
Revenue Growth
-2.65%
P/S Ratio
0.95
Revenue / Employee
6.55M
Employees
577
Market Cap
3.60B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 3.79B | 116.16M | 3.16% |
| Mar 31, 2024 | 3.68B | -310.92M | -7.80% |
| Mar 31, 2023 | 3.99B | 651.00M | 19.52% |
| Mar 31, 2022 | 3.34B | 261.64M | 8.51% |
| Mar 31, 2021 | 3.07B | 295.19M | 10.63% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Nectar Lifesciences | 16.70B |
| Ind-Swift Laboratories | 5.94B |
| Sigachi Industries | 4.85B |
| Beta Drugs | 3.85B |
| Jagsonpal Pharmaceuticals | 2.82B |
| Sakar Healthcare | 2.31B |
| Valiant Laboratories | 2.03B |
| Bafna Pharmaceuticals | 1.47B |
ZIM Laboratories News
- 14 days ago - Q2 2026 ZIM Laboratories Ltd Earnings Call Transcript - GuruFocus
- 7 weeks ago - Zim Laboratories Ltd (BOM:541400) Q3 2026 Earnings Call Highlights: Strong Export Growth Amid ... - GuruFocus
- 7 weeks ago - Q3 2026 ZIM Laboratories Ltd Earnings Call Transcript - GuruFocus
- 4 months ago - Why ZIM Laboratories has received CDSCO approval for its new Naproxen + Esomeprazole capsules - Business Upturn
- 8 months ago - ZIM Laboratories secures marketing authorization in Australia for urology drug combination - Business Upturn
- 9 months ago - ZIM Laboratories shares in focus as company gets first marketing approval in Australia - Business Upturn